Indication
Secondary Progressive Multiple Sclerosis
3 clinical trials
3 products
Product
MayzentClinical trial
Long Term Special Drug Use-results Surveillance for Mayzent in SPMS Patients (Prevention of Relapses and Delay of Progression of Physical Disability in Secondary Progressive Multiple Sclerosis)Status: Completed, Estimated PCD: 2023-08-30
Clinical trial
A Prospective, Single Center, Open Label, Dose Escalation Phase I/IIa Study to Assess the Safety and Efficacy of an Intrathecal Administration of SCM-010 in Subjects With Secondary Progressive Multiple Sclerosis (SPMS)Status: Withdrawn, Estimated PCD: 2025-02-01
Product
SCM-010Clinical trial
An Open-label, Non-randomized, Phase I Study of Allogeneic Placenta Derived Mesenchymal Stem Cells in Patients With Secondary-Progressive Multiple Sclerosis (SPMS),Status: Completed, Estimated PCD: 2024-03-04